R&D Platform
Seven R&D platforms
Anktiva™ Cancer Therapy Platform
- Activate immune cell function/survival/proliferation
- Achieve "broad-spectrum" anti-cancer effect
AnktivaTM (R&D code: ALT-803), a patented drug interleukin-15 (IL-15) superagonist independently developed by Altor BioScience, is a cooperative project between Beike Bioscience and the United States. The United States (FDA) has approved AnktivaTM for use in more than 30 clinical trials for a variety of diseases, including non-muscle-invasive bladder cancer and multiple myeloma. These clinical trials have shown that AnktivaTM has good safety and effectiveness. Beike Bioscience has obtained the exclusive development and sales rights of AnktivaTM in China.
Organoid R&D Platform
- Simulate the real organs of the human body to the greatest extent
- Disease Modeling
- Anticancer drug sensitivity screening
- Drug principle testing
- Personalized precision therapy
Organoids, as in vitro research models derived from three-dimensional stem cell culture, can be used for basic research such as regenerative medicine and disease mechanisms, as well as applied research such as drug sensitivity testing, personalized treatment, and drug screening. Beike Bio has successfully constructed mouse mammary organoids, human mammary organoids, and a library of breast cancer tumor organoids of various subtypes, and conducted drug sensitivity testing and personalized treatment research. It is expected to achieve clinical transformation of clinical drug screening and personalized precision treatment by 2024.
Human pluripotent stem cell research and development platform (transdifferentiation)
- Using directed differentiation and transdifferentiation techniques
- Obtaining specific types of functional cells
- Treating certain types of illnesses
Through the human pluripotent stem cell research and development platform, various types of functional cells are obtained by using directed differentiation and transdifferentiation technology, and treatment of various clinical indications such as diabetes, neurodegenerative diseases, genetic diseases, etc. Beike Bio has successfully established a production platform for obtaining induced pluripotent stem cells (iPSC) from peripheral blood and fibroblasts through cell reprogramming technology, and has built a technical system for directed differentiation of iPSC into various types of functional cells such as pancreatic β cells and neuronal cells, and established a technical route for transdifferentiation of fibroblasts into other types of functional cells. It is expected to initially complete the transformation to clinical application by 2026.
Empowering Mesenchymal Stem Cell R&D Platform
- Optimizing stem cell culture methods
- Grant specific abilities
- Achieve precision in different diseases
- Targeted therapy
The first-generation mesenchymal stem cell technology developed by Beike Biotechnology, “Key Technology Innovation and Clinical Application Research of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Systemic Lupus Erythematosus”, won the National Technological Invention Award in 2019. The second-generation mesenchymal stem cell technology developed by Beike Biotechnology has successfully used the empowered mesenchymal stem cell research and development platform to realize preclinical technology research on systemic lupus erythematosus (SLE) and knee osteoarthritis (KOA), and is expected to achieve clinical transformation and application in 2024.
Metabolomics R&D Platform
- Multidimensional health assessment and management
- Early diagnosis of diseases
- Drug target discovery
- Tumor benign or malignant judgment
- Disease efficacy and prognosis detection
Changes in human metabolites and their levels can reflect the results of the interaction between individual genes, living habits and living environment. The effective integration of advanced metabolomics analysis technology and health big data to form a scientific and efficient research and development platform has positive significance for clinical disease diagnosis, drug development, food safety and health management. From 2018 to 2020, 2,490 participants were recruited to complete the first phase of research and development of the Multi-Disease Diagnosis (MDTarg). By comparing the plasma and urine samples of the cancer group, healthy controls and disease controls, biomarkers for lung cancer, gastric cancer and colorectal cancer were discovered.
Biomaterials Platform
- For stem cells/exosomes
- Provide support
- Improve the cell growth microenvironment,
- Induced tissue reconstruction
It provides structural support for cells and can also induce tissue reconstruction by simulating the cell microenvironment of specific tissues. This platform mainly targets different indications, provides suitable carrier materials for the clinical application of stem cells and exosomes, synergistically promotes tissue regeneration, and gives the combined products a competitive advantage over similar products.
Build a technical platform for large-scale production and separation and purification of exosomes
- Building a large-scale exosome production platform
- Optimize the process to obtain high-purity exosomes
- Through exosome drug delivery & engineering transformation technology
- Achieve targeted treatment of different diseases
By building a large-scale exosome production technology platform to solve the difficulty of obtaining large quantities of high-purity exosomes, preclinical efficacy studies will be conducted in a variety of diseases such as skin diseases, respiratory diseases, neurodegenerative diseases, etc. in the future to promote its clinical transformation and application in the treatment of multiple clinical indications.
Expert Team
Hu Junyuan
PhD in Biochemistry and Molecular Biology, University of Gothenburg, Sweden and Chalmers University of Technology, Postdoctoral Fellow, University of British Columbia, Canada
- International Advisory Committee Member, UNICEF
- Vice Chairman of China National Stem Cell and Regenerative Medicine Industry Technology Innovation Strategic Alliance
- Executive Director of the Regenerative Medicine Technology Committee of China Pharmaceutical Biotechnology Association
- Winner of the Second Prize of the National Technological Invention Award in 2019
- Visiting Professor, Department of Surgery, The Chinese University of Hong Kong
- Executive Chairman of Xiongan International Health Forum
- Initiator of Boao Forum for Asia World Life Sciences Forum
- Chairman of Shenzhen Enterprise High-quality Development Promotion Association
- Shenzhen business leaders who have influenced China in the 40th anniversary of reform and opening up
- Chairman of Shenzhen Beike Biotechnology Co., Ltd.
- Dean of Shenzhen Beike Biotherapy Technology Clinical Translational Research Institute
Lothar Willmitzer
Member of the European Academy of Sciences, Member of the German Academy of Sciences
Founder and CSO of Pulse Map, graduated from the Center for Biotechnology Research, Technical University of Braunschweig in 1977 with a Ph.D. From 1994 to date, he has served as the Director (founding director) of the Institute of Plant Molecular Physiology at the Max Planck Institute in Potsdam, Germany, Professor at the University of Potsdam, Member of the European Academic Academy, German Academy of Sciences, European Molecular Biology Organization (EMBO), Member of the Berlin Academy of Sciences and Member of the Steering Committee. Professor Willmitzer enjoys an international reputation in the fields of plant physiology, plant biotechnology and metabolomics; he is one of the pioneering scientists in the field of metabolomics. To date, he has published more than 300 papers and academic works, including top academic journals such as Nature, Science, Cell, and the New England Journal of Medicine; and has applied for nearly 50 patents.
Yu Yang
PhD, leader of the Assisted Reproductive Engineering Research Group of Peking University Third Hospital, researcher, doctoral supervisor, deputy director of the Clinical Stem Cell Research Center, deputy director of the Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, winner of the National Natural Science Foundation of China Outstanding Youth Fund
In recent years, he has been engaged in basic research on assisted reproductive technology and stem cells, with a particular focus on safety evaluation of assisted reproductive technology (including technology and medication) and the establishment of stem cell disease models. He has undertaken 7 national scientific research projects and 3 provincial and ministerial scientific research projects. He has published 97 papers in SCI journals in related fields, and 63 research papers as the first or corresponding author in SCI journals, including Cell, Cell Research, Nature Communications, PNAS, etc., with more than 1,500 citations. Among them, the research results published in Cell and Stem Cell Reports in 2020 were selected as cover stories. He has been approved for 2 national invention patents, 1 utility model patent, and 1 international PCT patent. His research results won the second prize of the 2013 Huaxia Medical Science and Technology Award, the first prize of the 2015 Beijing Science and Technology Award, the first prize of the 2016 Huaxia Medical Science and Technology Award, the second prize of the 2017 National Science and Technology Progress Award, the first prize of the 2018 Chinese Medical Science and Technology Award, and he was selected as an outstanding young talent in Beijing, a new star in Beijing Science and Technology Training Program, and the 2018 Fellowship Award of the Milstein Asian American (MMAAP) Foundation in the United States. He is currently the academic editor of the international SCI academic journal PLoS ONE and Frontiers in Endocrinology.
Jiang Wei
PhD, Professor and Doctoral Supervisor at Wuhan University Medical Research Institute
PhD in Cell Biology from the School of Life Sciences, Peking University. Postdoctoral fellow at the Howard Hughes Medical Institute and the University of North Carolina at Chapel Hill. Professor at the School of Medicine, Wuhan University, and distinguished researcher at Zhongnan Hospital. His main research directions are stem cell differentiation, epigenetic regulation, long noncoding RNA, disease models, and diabetes. He has published more than 30 papers in international journals, which have been cited more than 2,000 times by SCI, and the highest number of citations for a single first-author paper is more than 300 times. In the past five years, he has published many papers as the corresponding author in international academic journals such as Nature Communications, Nuclear Acid Research, Cell Reports, Stem Cell Reports, and Stem Cells. He has been invited to give oral reports at the ISSCR conference and several international conferences in Japan and South Korea. His research is supported by the High-level Talent Program of the Organization Department of the CPC Central Committee and the Major Research Program Cultivation Project of the National Natural Science Foundation of China.
Wang Zhihua
Researcher/doctoral supervisor at the State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences, researcher at Shenzhen Hospital, Fuwai Hospital, Chinese Academy of Medical Sciences, winner of the National Natural Science Foundation of China Outstanding Youth Fund
His research direction is pathological myocardial hypertrophy and cardiac aging. He analyzes the molecular mechanisms of pathological growth and aging of cardiomyocytes from different dimensions such as epigenetics, gene transcription, protein translation, and metabolic networks, and conducts drug development and translational research. He serves as a director of the China Association of Young Scientists and Technologists, a member of the Circulatory Physiology Committee of the Chinese Physiological Society, a member of the Cardiovascular Professional Youth Committee of the Chinese Society of Pathophysiology, and deputy editor-in-chief of Front Cardiovasc Med. He has been granted 5 national invention patents. He has presided over scientific research projects such as the National Natural Science Foundation of China’s general/excellent young projects, the Guangdong Provincial Foundation of China’s general projects, and the Shenzhen Science and Technology Innovation Commission’s outstanding young projects. He has published 40 research papers in professional journals such as Nature Medicine, Circulation, Circulation Research, Hypertension, and Front Cell Dev Biol. He has participated in the editing of monographs such as Epigenetics Methods, Basic and Clinical Cardiovascular Physiology, and Encyclopedia of Chinese Medicine, and presided over the special issue of Epigenetic Regulations in Cardiovascular Diseases.
Cai Cheguo
PhD, Professor and Doctoral Supervisor at University of Science and Technology of China Hangzhou Institute for Advanced Studies, Vice President and Chief Scientist of Beike Biotechnology
He received his bachelor’s, master’s and doctoral degrees from Xiamen University and the Chinese Academy of Sciences, respectively, and completed postdoctoral training at Tulane University School of Medicine and the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. He is mainly engaged in research related to adult stem cells and organ development, and has published many articles in internationally renowned journals such as Nature, Genes & Development, Elife, Cell Research, PLoS Genetics, Cell Reports, npj Regenerative Medicine, Journal of Experimental & Clinical Cancer Research, etc. As the person in charge, he presided over many projects such as the National Natural Science Foundation of China, the Ministry of Science and Technology, and the Chinese Academy of Sciences. He is a national leading talent in Shenzhen, a member of the International Stem Cell Society, and the Chinese Society of Cell Biology. He is a judge of the National Natural Science Foundation and Shenzhen Science and Technology Innovation Commission fund projects, and an editorial board member and review expert of many international journals.
Liang Xiao
Vice President of Beike Biotechnology
Vice President of Beike Biotechnology, Senior Engineer of Cell Preparation
Wang Jinsong
PhD
Doctor of Medicine, Guangzhou Medical University
Liang Xiao
Vice President of Beike Biotechnology
Vice President of Beike Biotechnology, Senior Engineer of Cell Preparation
Wang Jinsong
PhD
Doctor of Medicine, Guangzhou Medical University
Li Yan
PhD
PhD in Biochemistry, Max Planck Institute of Molecular Plant Physiology, Germany
Liao Yan
Postdoctoral fellow
PhD and Postdoctoral Fellow, Basic Medicine (Stem Cells and Tissue Engineering), Zhongshan School of Medicine, Sun Yat-sen University
Gao Yunfeng
PhD
PhD, School of Food Science and Biotechnology, Tianjin University of Science and Technology
Dai Yonghui
PhD
PhD in Cell Biology, Southern Medical University
Zhang Mengna
Postdoctoral fellow
PhD, School of Medicine, Wuhan University, Postdoctoral Fellow, University of Science and Technology of China Hangzhou Institute for Advanced Studies
Ding Mina
PhD
PhD in Biomedical Sciences, Chonnam National University, South Korea
Liu Chuntao
PhD
Master of Polymer Chemistry and Physics, PhD in Biomedical Engineering, Sun Yat-sen University
Zheng Ran
PhD
PhD in Biology, Medical Research Institute, Wuhan University
Wu Bingyan
PhD
PhD in Cell Biology, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Clinical research collaboration projects
So far, a total of 5 medical institutions have successfully passed the registration of stem cell clinical research institutions by the National Health Commission in cooperation with Beike Biotechnology.
Government Cooperation Projects
Mesenchymal stem cell clinical research projects in which Beike Biotech participated
Mesenchymal stem cell clinical research projects in which Beike Biotech participated
| Project | Hospital |
|---|---|
|
A randomized, parallel, controlled study on the safety and efficacy of umbilical cord mesenchymal stem cells in the treatment of type 2 diabetes via different transplantation routes |
Peking University Shenzhen Hospital |
|
Clinical study on the safety and effectiveness of umbilical cord mesenchymal stem cells combined with modern rehabilitation in the treatment of cerebral palsy in children |
Shiyan Taihe Hospital |
|
A randomized, blinded, parallel controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis |
Nanjing Drum Tower Hospital |
|
A randomized, blinded, parallel controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis |
Jiangsu Provincial People’s Hospital |
|
A randomized, blinded, parallel controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis |
Fudan Zhongshan Hospital |
|
A randomized, blinded, parallel controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis |
Shanghai Huashan Hospital |
|
A randomized, blinded, parallel controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis |
Shanghai Renji Hospital |
|
A randomized, blinded, parallel controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis |
The First Affiliated Hospital of Baotou Medical College |
|
A randomized, blinded, parallel controlled multicenter study of umbilical cord mesenchymal stem cells in the treatment of lupus nephritis |
The Affiliated Hospital of Nantong University |
|
Clinical application of umbilical cord mesenchymal stem cells in the treatment of moderate to severe refractory systemic lupus erythematosus |
Anhui Provincial Hospital |
|
To evaluate the efficacy of intra-articular injection of human umbilical cord mesenchymal stem cells in the treatment of knee osteoarthritis |
Beijing Hospital |
COVID-19 clinical research projects:
| Project | Hospital |
|---|---|
|
Clinical study of human umbilical cord mesenchymal stem cells in the treatment of severe pneumonia caused by coronavirus |
Shenzhen Third People’s Hospital |
|
Clinical study on mesenchymal stem cells in the treatment of severe coronavirus pneumonia |
Department of Emergency Medicine, The First Affiliated Hospital of Kunming Medical University |